Doris
M. Benbrook, Ph.D.
University of
Department of Obstetrics and Gynecology FAX: (405) 271-2968
Section of Gynecologic Oncology E-mail: Doris-Benbrook@ouhsc.edu
1977 to 1981
Bachelor
of Arts, majors in Biology and Chemistry, minor in German.
1981 to 1985
Ph.D.
in Biochemistry,
1985 to 1988 In the laboratory of Magnus Pfahl,
Ph.D.
10901
North Torrey
1988
to 1991 In
the laboratory of Nicholas C. Jones, Ph.D.
Imperial
Cancer Research Fund,
44
2004 – present Professor and Director of Research
1997- present Associate Professor and Director of Research
1991- present Assistant Professor
1993 – present Director of Research
Department
of Obstetrics and Gynecology, Gynecologic Oncology Section
University
of
1997-present Adjunct Associate Professor
1993-1997 Adjunct
Assistant Professor
Department
of Biochemistry and Molecular Biology
University
of
1993 – present Associate Member of the Graduate Faculty
University
of
1995 – present Vice Chair of the Institutional Biosafety
Committee (IBC)
University
of
2001- present Co-Director, Gynecologic Cancer Program
2002 – present Scientific Review Board Member
AWARDS AND HONORS
2004 Oklahoma Scientist of the Year
awarded by the Oklahoma Acedemy of Science
2004 Woman of the Year Nominee awarded by
the Journal Record.
National committees AND
Societies
Chair of the
National Cancer Institute (NCI) Chemoprevention Committee, Subcommittee E,
Cancer Epidemiology, Prevention and Control, 2003-2005.
Member of NCI
Chemoprevention Committee, Subcommittee E, Cancer Epidemiology, Prevention and
Control, 2000-2005.
Gynecological
Oncology Group (GOG), Member of the Experimental Medicine Committee (since
1992) and Member of Chemoprevention Committee (since 2000).
Associate
Editor Cancer Epidemiology, Biomarkers & Prevention, 2002-2005.
Member of NCI ZRG1 Cancer Biomarkers Study Section
(CBSS), 2004 - present
Reviwer for Phillip
Morris External Research Program, 2003
Reviewer of
Department of Defense Ovarian Cancer Grants, 2002 - 2003.
Department of
Veterans Affairs’ Medical Research Branch ad hoc grant reviewer since 1992 and
nominated for their National Advisory Committee, 2002.
NCI Reviewer
for “Clinical Nutrition Research Units”, December 2001
Co-Chair of
Chemoprevention Workshop for the Gynecologic Cancer Translational Research
Retreat II,
NCI Scientific
Review Group Subcommittee E, Cancer Epidemiology, Prevention and Control
Temporary Member, April 2000.
NCI Reviewer
for “Molecular Target Drug Discovery”, 2000.
NCI Reviewer
for "The Early Detection Research
Network- Clinical and Epidemiologic Centers.
NCI Reviewer
for “Chemoprevention in Genetically-Identified High-Risk Groups: Interactive
Research and Development Projects”.
NCI
Chemoprevention Committee Site Visit Reviewer, June 1999 and January, 2000.
Ad Hoc reviewer
for American Journal of Obstetrics and
Gynecology, Analytica Chimica Acta, Blood, Cancer, Cancer Letters, Cancer
Investigation, Cancer Research, CRC Press, Experimental Cell Research, Fertility and Sterility, Journal of
Biochemistry, Journa
of the National Cancer Institute, Journal
of Neurochemistry, and Journal of Surgical Oncology, Pharmaceutical Research.
American
Association for Cancer Research, Chairman of State Legislative Committee.
American
Society of Clinical Oncologists (ASCO), Cancer Genetics Trainer
Referee for the
Italian Research Council, 2002 & 2003
Reveiwer of grants for
Cancer Reseach
UNIVERSITY COMMITTEES
OU
Outstanding
Thesis/Disertation Committee, 2000-2001
Faculty Affair Liaision, 2002
Obstetrics and
Gynecology
Director of Research, 1995 - present
Environmental Health and Safety Training
Co-ordinator, 1995- present
Tuberculosis Co-ordinator,
1996- present
Research Administration Liaision – 1994 -
present
Biochemistry Department
Graduate Program Curriculum/Review Committee, 1995-97
Adjunct Faculty Review and Evaluation Committee, 1997-2000
Student Advisory Committee, 2001-02
Student
Admissions and Advisory Committee, 2002-2003
Dental/Pharmacy
Course Curriculum Committee, 2003-2004
ASCO trainer in Cancer
Genetics
Integrated Graduate Student Curriculum
·
Regulation
of Gene Expression (4.5 hours), 2002 - present
·
Oncogenes and Tumor Suppressor Genes (4 hours),
2001- present
·
Nucleic
Acids: RNA Splicing Mechanisms (4
Hours), 2000
·
Current issues in Biomedical Research: Clinical Trials
(2 Hours), 2000 – present
·
Cancer Journal Club, 2002-2003
Biochemisty Curriculum prior to
2000
·
Biochemistry
6234: DNA tumor viruses and Chemical Carcinogenesis (4 hours)
·
Biochemistry
5224: DNA Sequencing and EMSA (2 hours)
·
Biochemistry
6224: 7 week laboratory rotations for Graduate Students.
·
Biochemistry
6980: Chair of Ph.D. thesis committee of
Shennan Lu “Mechanism of Growth Inhibition by Retinoids”.
·
Biochemistry
6980: Chair of Ph.D. thesis committee of
Suresh Guruswamy.
·
Biochemistry
6502: Advanced Topics in Human Molecular Genetics (2 hours)
·
Biochemistry
5970: Student Research Seminar, 1 hour per week
Dental Biochemistry:
Carcinogenesis, 1 hour, 1999-2001
Annual
Lectures on Oncogenes and Tumor Supressor
Genes in the Departments of Pathology and Radiological Sciences, 1993 -
present.
Ph.D.
comprehensive qualifying written exams and qualifying oral examination
committees
Annual Obstetrics and
Gynecology Grand Rounds Lectures with various topics.
Kim Kyker Biochemistry
and Molecular Biology Ph.D.
Candidate
Shankar Sachithanandam Radiological
Sciences Ph.D.
Candidate
Ahmed Mohamed Mahmoud
Abou-Eisha,
Dustin Smith Biochemistry and Molecular
Biology Ph.D. Candidate
Richard Langeras Biochemistry and
Molecular Biology Ph.D.
Candidate
Mathew S. Gibson Cell Biology Ph.D.
Candidate
Staphanie Si Liu Biochemistry,
Evelyn
Rosas Nuñez, M.D. Gynecologic
Oncology 1994-1995
Rick Erikson MD
Otorhynolaryngology 1994-1995
Cole Flanagan, M.D. Gynecologic
Oncology 1995-1996
Janet Larsen, M.D. Maternal Fetal Medicine 1995-1996
Tim Zacheis,
M.D. Otorhynolaryngology 1995-1996
Jane Shen-Gunther,
M.D. Gynecologic
Oncology 1996-1997
Paul A DiSilvestro,
M.D. Gynecologic
Oncology 1996-1997
Todd Ivey, M.D. Gynecologic Oncology 1997-1998
Michael Gold, M.D. Gynecologic
Oncology 1998-1999
Scott Kamelle, M.D. Gynecologic
Oncology 1999-2000
Avi Khafif, MD, Otorhynolaryngology 1999-2000
Dennis Scribner, M.D. Gynecologic Oncology 2000-2001
Todd Tillmanns, M.D. Gynecologic Oncology 2000-2001
Natalie
Gould, M.D. Gynecologic
Oncology 2001-2002
Teresa
Rutledge, M.D. Gynecologic
Oncology 2001-2002
Camille
Falkner, M.D. Gynecologic
Oncology 2002-2004
Daynelle
Dearnley, M.D. Gynecologic
Oncology 2004-2005
GRADUATE RESEARCH PROJECTS MENTORED
Coy Heldermon Biochemistry 1992
Kent Rodgers Biochemistry 1993
Terry Kay Epperson Biochemistry 1994
Hai Ying Qui Biochemistry 1996
Suresh Guruswamy Biochemistry 1997
Xiaohong Zhong Biochemistry 1997
Bahara Ebadifar Graduate Program in Biomedical Sciences (GPiBS) ResearchRotation 2003
Anne Murray GPiBS
Research Rotation, 2003
Julie Scott GPiBS Research Rotation, 2003
RESIDENT RESEARCH PROJECTS MENTORED
Dana Stone, M.D. Obstetrics and Gynecology Resident 1997–1998
Carla Spencer, M.D. Obstetrics and Gynecology
Resident 1998-1999
Nefertiti DuPont, M.D. Obstetrics and Gynecology Resident 1999–2003
MEDICAL STUDENT RESEARCH PROJECTS MENTORED
Rod
Cassandra Onofre y Medical
Student Summer Research Project 1993
Virginia Fishburne
Medical Student Summer
Research Project 1997
Marylin Webster Medical Student Summer
Research Project 1998
UNDERGRADUATE STUDENT RESEARCH PROJECTS MENTORED
Amy Noll, B.S. Summer Pre-graduate Student 2003
Ashley Hopkins Summer Undergraduate Research Experience
(SURE) 2003
Jen’nea Ose,
B.S. Biomedical
Research Infrastructure Network (BRIN) 2003
Barbara Jeske Summer Undergraduate Research Experience
(SURE) 2004
HIGH SCHOOL STUDENT/TEACHER RESEARCH PROJECTS MENTORED
Anjan Shah High School
Student,
Lulla Moore
Anjan Shah School of Math
and Science, Winter Semester 1992
Mary Ruth Boone Minority Program, High School Student, Summer 1993
Kelly Jester
Jacqueline Maliwat Summar
Minority Program, 1996
Ebony Allen Summer Minority Program 1996
Kayla Brooks Science Fair Project, Regional Winner 2001
Kelsie Brooks Science Fair
Project, Regional Winner 2003
PATENTS
Co-inventor:
Heteroarotinoids containing urea or thiourea linker Serial No. 09/824,547
Co-inventor:
Novel Orphan Receptor Interacting With Retinoid/Thyroid Hormone Receptor
Subfamily (Ref. No. 1212.017)
Co-inventor: Heteroarotinoids-Anticancer
Agents with Receptor Specificity and TGase Activity.
CURRENT
FUNDING
Rapid Access to Intervention Development
(RAID)
SHetA2 will Inhibit Cancer Recurrence
Without Retinoid-Associated Toxcities.
$2,083,000 for preclinical testing of
SHetA2.
Principal
Investigator: Doris M. Benbrook, Ph.D.
National Cancer Institute Program
Planning Grant for NCI Cancer Research Centers (PAR-00-011),
Director: Howard Ozer, MD, Co-Program Leader: Doris M. Benbrook, Ph.D.
7/01/02-6/30/07 $925,084
National
Cancer Institute, National Institutes of Health
A Murine Model of Endometrial Tumorigenesis
Principal Investigator: Paul Goodfellow at
Doris M. Benbrook: Co-Investigator
Mary
Kay Ash Charitable Foundation
Mechanism of ER Activation in Thyroid
Hormone Administration in Breast Cancer
Survivors
The major goals are to evaluate the
estrogenic activity of thyroid hormone.
Role: Co-Investigator
Novartis Pharmaceutical through PRA International
Phase II Trial of Gleevec
(Imatinib Mesylate Formerly
Known as STI571) in Patients with CD1q17(+) Gynecologic Malignancies
Principal Investigator: D. Scott McMeekin, M.D.
Co-P.I., Doris M. Benbrook, Ph.D.
“Does HPV16 E5 affect EGF Receptor Endocytosis and Signaling?"
Principal Investigator: Brian Ceresa,
Ph.D.
Co-Investigator: Doris M. Benbrook, Ph.D. (5%)
$135,000
Gynecologic Oncology Group
“Analysis for
GOG229-B, GOG230-B, GOG-231-B Stage I”
Principal
Investigator, Doris M. Benbrook, Ph.D.
PAST FUNDING
“Mechanism & Potential of Retinoid
& DNA Damage Therapy.”
Principal
Investigator: Doris M. Benbrook, Ph.D.
”Is Retinoid Induced Cell Apoptosis Mediated
by Superoxide Radical Anion Production?”
Principal
Investigator: William J. Kelly, Ph.D.
Collaborating
Investigator: Doris M. Benbrook, Ph.D.
(5%)
02/01/04-06/30/04, $50,000
Procter & Gamble
“Determination
of Retinoid X Receptor Ligand Structure-Function Properties”
Principal
Investigator: Doris M. Benbrook, Ph.D.
“Human Papillomavirus and Epidermal Growth Factor Receptor as
Biomarkers of Retinoid Cervix Cancer Chemoprevention”
Principal
Investigator: Doris M. Benbrook, Ph.D.
Postodoctroal Fellow:
Shennan Lu
“Laboratory
Support Agreement to Develop and Perform ELISA’s for
Neo-MS-02 Clinical Trial”
Principal
Investigator: Doris M. Benbrook, Ph.D.
05/01/2000-
06/30/02, $72,000
Procter & Gamble
Consulting Agreements
Procter & Gamble
“Determination of Retinoid Receptor
Transactivation Properities”
American Institute for Cancer Research
(AICR)
“Ligand
Activation of Peroxisome Proliferator-Activated
Receptors in Rodent Mammary Tumor Models.”,
Principal
Investigator: Stephen Glore, Ph.D.
Collaborator:
Doris M. Benbrook, Ph.D.
"Development
of Retinoids and Response Biomarkers for Ovarian Cancer."
Principal
Investigator: Doris M. Benbrook, Ph.D.
National Cancer Institute, National
Institutes of Health,
“Biological
Activity of Heteroarotinoids.”
Principal
Investigator: Eldon C. Nelson, Ph.D.,
Co-investigator:
Doris M. Benbrook
"Carotenoid Effects on Transcription and Growth in
Tumors."
Principal
Investigator: Doris M. Benbrook
The Presbyterian Health Foundation,
"Radiation
and Retinoid Effects on Cervical Cancer."
Principal
Investigator: Doris M. Benbrook, Ph.D.
National Science Foundation, MCB-9209479,
"DNA
Binding Specificities of cJun Dimers."
Principal Investigator:
Doris M. Benbrook, Ph.D.
Milheim Foundation for
Cancer Research, 92-14
"Retinoids,
cJun and Cervical Cancer."
Principal
Investigator: Doris M. Benbrook, Ph.D.
"Retinoids,
cJun and Cervical Cancer."
Principal
Investigator: Doris M. Benbrook, Ph.D.
Presbyterian Health Foundation, Research
Equipment Repair Fund,
Principal
Investigator: Doris M. Benbrook, Ph.D.
1992, $5,000
for repair of an ultracentrifuge.
A
randomized study of tamoxifen verses thalidomide in
patients with biochemical-recurrence-only epithelial ovarian cancer, cancer of
the fallopian tube, and primary peritoneal cancer after first line
chemotherapy.
A
phase II evaluation of thalidomide in the treatment of recurrent or persistent
endometrial carcinoma.
A
phase II evaluation of thalidomide in the treatment of recurrent or persistent carcinosarcoma of the uterus.
A phase II evaluation of thalidomide in
the treatment of recurrent or persistent leiomyosarcoma
of the uterus.
Gynecologic Oncology Group (GOG) Protocol
# CEM0208
Study Chair: Doris M. Benbrook, Ph.D.
Study Co-chairs: Robert S. Mannel, M.D.,
Elise Kohn, M.D.,
Comparison
of Glycoprotein Expression and T-Synthase Function in
Primary versus Metastatic Tumors.
Study Chair: Michael Gold, M.D.
Study Co-Chairs: Doris M. Benbrook, Ph.D., Richard Cummings,
Ph.D.,
A Randomized Double-Blind Phase II Trial
of Celecoxib, a Cox 2 Inhibitor, in the Treatment of
Patients with Cervical Intraepithelial Neoplasia 3
(CIN3).
Study Chair:
Janet Rader, M.D.
Translational
Research Chair: Doris M. Benbrook, Ph.D.
1. Benbrook, D.M. and Miller,
R.V. (1986) Effects of Norfloxacin on DNA metabolism in pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 29:
1-6.
2. Benbrook, D. & Pfahl, M. (1987) A
Novel Thyroid Hormone Receptor Encoded by a cDNA Clone from a Human Testis
Library. Science, 238: 788-791.
3. Pfahl, M. & Benbrook,
D. (1987) Nucleotide Sequence of
cDNA Encoding a Novel Thyroid Hormone Receptor.
Nucleic Acids Research, 15:
9613.
4. Benbrook, D., Lernhardt, E. & Pfahl, M.
(1988) A New Retinoic Acid Receptor
Identified from a Hepatocellular Carcinoma. Nature, 333:
669-672.
5. Benbrook,
6. Benbrook, D.M. & Jones,
N.C. (1994) Different Binding
Specificities and Transactivation of Variant CRE's by
CREB complexes. Nucleic Acids Research, 22: 1463-1469.
7. Apfel, R., Benbrook,
D., Lernhardt, E., Ortiz, M.A., and Pfahl, M. (1994) A
novel orphan receptor specific for a subset of thyroid hormone-response
elements and its interaction with the retinoid/thyroid hormone receptor
subfamily. Molecular and Cellular Biology,
14: 7015-7035.
8. Benbrook, D.,
9.
Benbrook, D. M., Shen-Gunther,
J., Nuñez, E.R., Dynlacht, J.R. (1997)
Differential retinoic acid radiosensitization of cervical carcinoma cell
lines. Clinical Cancer Research, 3: 939-945.
10. Johnson, G.A.,
Mannel, R.S., Khalifa, M.,
11. Benbrook, D.M., Lu, S.,
Flanagan, C., Shen-Gunther, J., Angros,
L.H., Lightfoot,
12. Miller, A.M., Sahl, W.J., Brown, S.A., Young, S.K., Quinlan, C.M., Patel,
P.R., Benbrook, D.M., Naylor, M.F.
(1997) The role of human papillomavirus in the development of pyogenic
granulomas. International Journal of Dermatology, 38:
101-105.
13. Benbrook,
D.M., Madler, M.M., Spruce, L.W., Birckbichler, P., Nelson, E.C., Subramanian, S., Weerasekare, G.M., Gale, J.B., Patterson, Jr., M.K., Wang,
B., Wang, W., Lu, S., Rowland, T.C., DiSilvestro, P.,
14. Madler, M.M., Klucik,
J., Soell, P.S., Brown, C.W., Liu, S.,
15. Benbrook,
D.M., Subramanian, S., Gale, J.B., Liu, S., Brown, C.W., Boehm, M.F.,
16. DiSilvestro, P.A.,
17. Waliszewski, P. Waliszewski,
M., Gordon, N.,
18. Liu,
19. Dhar,A., Liu,S., Berlin, K.D., Madler,
M.M., Ivey, R.T., Birckbichler, P.J., Lu, S., Zacheis, D., Brown, C.W., Klucik,
J., Nelson, E.C., Benbrook, D.M. (1999) Synthesis and Structure-Activity
Relationships of Nitrogen Heteroarotinoids.
Journal of Medicinal Chemistry, 42:
3602-3614.
20. Zacheis, D., Dhar, A.,
Lu, S., Madler, M.M., Klucik,
J. Brown, C.w., Liu, S., Clement, F., Subramanian,
S., Weerasekare, G.M., Berlin, K.D., Gold, M., Houck,
J.R., Fountain, K.R., Benbrook, D.M.
(1999) Heteroarotinoids inhibit
the growth of head and neck cancer cell lines in vitro and in vivo
through both RAR and RXR retinoic acid receptors. Journal
of Medicinal Chemistry, 42:
4434-4445.
21. Salsman,
S., Lu, S., Benbrook, D.M.
(1999) The mechanism of retinoid
radiosensitization is independent of AP-1 repression in cervical carcinoma
cells. Gynecologic Oncoology, 73: 253-256.
22. Hurst, R.E. Waliszewski, P. Waliszewska, M.
Bonner, R.B. Benbrook, D.M.
Dhar, A. Hemstreet, G.P 3rd. Complexity,
retinoid-responsive gene networks, and bladder carcinogenesis. Advances in
Experimental Medicine & Biology. 462: 449-67.
23. Simoni,
D., Roberti, M.,” Invidiata,
F.P., Rondanin, R., Baruchello, R., Malagutti, C., Mazzali, A., Rossi,
M., Grimaudo, S., Dusonchet,
L., Meli, M., Raimondi,
M.V., Landino, M., D’Alessandro, N., Tolomeo, M.,
Dhar, A., Lu, S. Benbrook,
D.M. (2001) Heterocycle-Containing
Retinoids. Discovery of a Novel Isoxazole Arotinoid
Possessing Potent Apoptotic Activity in Multidrug and
Drug-Induced Apoptosis Resistant Cells. Journal of Medicinal Chemistry, 44:2308-2318.
24. Guruswamy, S.,
Lightfoot, S., Gold, M., Hassan, R., K. Darrell Berlin, Ivey, T.R., Benbrook,
D.M. (2001) Effects of Retinoids on the Cancer Phenotype
and Apoptosis in Organotypic Cultures of Ovarian Carcinoma. Journal of the National Cancer Institute, 93: 516-525.
25. Scribner, D., Benbrook,
D.M. (2002) Retinoids Enhance Cisplatin-based Chemoradiation in Cervical Cancer Cells In Vitro. Gynecologic Oncology, 85:
223-225.
26. Kamelle, S., Sienko, A., Benbrook, D.M. (2002) A Hormonally Responsive Model of
Cycling Endometrium. Fertility & Sterility, 78 (3): 596-602.
27. Hassan, R.,
Lerner, M.R., Benbrook, D.M., Lightfoot, S.A., Brackett, D.J., Wang,
Q.-C., Pastan, I. (2002) Anti-tumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38,
recombinant anti-mesothelin immunotoxins
against human gynecologic cancers grown in organotypic culture in vitro. Clinical Cancer Research, 8:
3520-3526.
28. Benbrook, D.M. (2003) An ELISA method for detection of human
antibodies to an immunotoxin. Journal of Pharmacological and Toxological Methods. 47: 169-175.
29. Mic, F. A., Molotkov, A., Benbrook, D. M., and Duester, G. (2003)
Retinoid activation of RAR but not RXR is sufficient for mouse embryonic
development. Proceedings of the
National Academy of Sciences. 100: 7135-7140.
30. Chun, K.-H.,
Benbrook, D. M., Berlin, K. D., Honk, W. K., and Lotan, R. (2003) Induction of
apoptosis in head and neck squamous cell carcinoma (HNSCC) cell lines by
heteroarotinoids through a mitochondrial dependent pathway. Cancer Research, 63: 3826-3832.
31. Liu, S., Brown,
C.W., Berlin, K.D., Dhar, A., Guruswamy, S., Brown, D., Gardner, G.J., Birrer,
M., J., & Benbrook, D.M. (2004) Synthesis of flexible sulfur-containing
heteroarotinoids that induce apoptosis and reactive oxygen species with
discrimination between malignant and benign cells. J. Med. Chem., 47:
999-1007.
32. Brown, C.S.,
Liu, S, Klucik, J., Brown, C.W., Berlin, K. D.,
Brennan, P.J., Devinder, K., Benbrook, D.M. (2004) Novel heteroarotinoids as
potential antagonists of Mycobacterium Bovis BCG. J. Med. Chem, 47: 1008-1017.
33. Subramanian,
S., Smith, C.M., Tabatabai, T., Bryan, C.D., Buettner, B., Hale, S., Wakefield, C.A., Benbrook, D.M.,
Berlin, K.D. Synthesis of novel heteroarotinoids with receptor activation
capabilities and TGase activity. Single crystal analysis of (E)-4-
34. Kamelle, S.A.,
Guruswamy, S.B., Lightfoot, S.A., Rutledge, T.L., Gould, N.S., Dunn, S.T.,
Berlin, K.D., Benbrook, D.M. Flexible
Heteroarotinoids (Flex-Hets) Exhibit Improved Therapeutic Ratios as Anti-Cancer
Agents Over Retinoic Acid Receptor Agonists.
(2005) Investigational New
Drugs. Accepted provisionally with
changes.
35. Tillmans, T.D.,
Kamelle, S.A., Guruswamy, S., Gould, N.S., Rutledge, T.L., Benbrook, D.M. (2005) Sensitization of Cervical Cancer Cell
Lines to Low Dose Radiation by Retinoic Acid Does Not Require Functional p53. Gynecologic
Oncology, in press.
1. Pfahl, M., Payne,
J., Benbrook, D. & Wu, K.C. (1988)
Differential Activation of a Hormone-Responsive Element in Various Cell
Lines. Steroid Hormone Action, pp. 161-168.
2. Benbrook, D.M., Tonetti, D.A. & Miller, R.V. (1989) DNA Gyrase of Pseudomonas Aeruginosa:
Inhibition by Quinolones. Proceedings
International Telesymposium on Quinolones,
Fernandez, P.B. (Ed.) J.R. Prous Science
Publishers, pp.171-186.
3.
Alberts, D.A., Barakat,
R.R., Daly, M., Method, M.W., Benbrook, D.M., et al. (2004) Prevention of
Gynecologic Malignacies. In Gershensen,
D.M., McGGuire, W.P., Gore, M., Quinn, M.A., Thomas,
G. editors. Gynecologic
Cancer: Controversies in Management. Elsevier, Churchill, Livingston,
Philadelphia, PA.
Benbrook, D.M., Wilkerson, J.
C. (2003) Nature Reviews Cancer. JAMA. 289(8):1049-1050.
1. Rogers, R.S., Benbrook,
D.M., Walker, J.L., Lord, B.J., Haas, G.G.
(1992) “Silent” carriers of human papillomavirus
(HPV) identified in sperm bank donor population. Proceedings of the American
Fertility Society, 48th Annual Meeting.
2. Benbrook, D.M., Medlin, M.,
Rogers, R., Ahern-Moore, J., Dunn, S.T., Lord, B., Walker, J.L. (1993)
“Retinoid effects on tumor cells in organotypic culture.” American
Association for Cancer Research Special Conference “Mechanism of Action of
Retinoids, Vitamin D, and Steroid Hormones.”
3. Benbrook, D. M., Heldermon, C., Nunez, E.R., and Waliszewski,
P. (1994) Retinoic acid receptor RAR effects in cervical tumor cell
lines. Diet and Cancer: Molecular Mechanisms of Interactions, American
Institute of Cancer Research.
4. Benbrook, D. M., Heldermon, C. (1994)
Retinoic acid receptors bind to HPV16LCR sequence and repress
transcription indirectly through AP1 sites.
Proceedings of the 13th
International Papillomavirus Conference.
5. Mannel, R. S., Khalifa, M., Wren, M., Walker, J.L., Min, K.-W., Benbrook,
D.M. (1994) Epidermal growth factor receptor in
vulvar malignancies and its relationship to metastasis and patient
survival. 26th Annual Society of Gynecologic Oncologists’ Meeting.
6. Waliszewski, P., Benbrook,
D., Nasim, M., Hurst, R.E. (1995) "Human uroepithelial
cells contain retinoid signaling pathways." Proceedings of the American Association for Cancer Research, 36:630.
7. Waliszewski, P., Benbrook,
D., Blaszewski, M.K., Gupta, M., Drews, M., Hurst, R.E. (1995) The retinoic acid signaling pathway in normal
and transformed human intestinal epithelial cells. Proceedings
of the American Association for Cancer Research, 36:601.
8. Nuñez, E.R., Heldermon, C., Benbrook, D.M. (1995) Restoration of RAR expression and function in RAR-deficient cervical tumor cell lines has
different effects depending on the intercellular environment. American
Association for Cancer Research Conference "Mechanism of Action of
Retinoids, Vitamin D and Steroid Hormones".
9. Nuñez, E.R., Benbrook,
D. M. (1995) Retinoic acid receptor
expression effects growth and retinoid sensitivity in cervical tumor cell
lines. American Association for Cancer Research Conference "Molecular
Biology of Cancer: Implications for Prevention and Therapy".
10. Nuñez, E.R., Benbrook,
D.M., Berlin, K.D., Nelson, E.C. (1995)
A heteroarotinoid affects growth and transactivation of a retinoic acid
response element in cervical carcinoma cell lines. The
FASEB Journal, 9(3, part 1):
985.
11. Benbrook, D. M., Jordan,
T.L., Heldermon, C. and Robinson, K. (1995) Evaluation of endogenous retinoic acid
receptor function in cervical tumor cells. Dietary Phytochemicals
in Cancer Prevention and Treatment, 62.
12. Nuñez, E.R., Jordan,
T.L., Benbrook, D.M. (1996)
13-Cis acid is a radiosensitizer of SiHa
cervical carcinoma cell line. Proceedings of the American Association for
Cancer Research. 37:4144.
13. Madler, M., Benbrook,
D.M. Birckbichler, P.J., Nelson, E.C., Berlin,
K.D. (1996) Biologically active
heteroarotinoids. Presented at the Annual
Meeting of the Medicinal Chemistry Division of the American Chemical Society,
August 96.
14. Oian, X., Benbrook,
D.M., Berlin, K.D., Cushman, J.C., Madler, M.M.,
Patrick, S.D., Simms, M.D., Nelson, E.S.
(1996) Comparative effects of a diaryl heteroarotinoid and
all-trans-retinoic acid on induction of differentiation. The
FASEB Journal, 10:4390.
15. Benbrook, D.M., Lu, S.,
Flanagan, C.W., Jordan, T.L. (1996)
Retinoids inhibit growth and activate endogenous receptors in a cervical
tumor cell line. Presented at the 1996 FASEB Summer Research Conference on
Retinoids.
16. Lu, S.,
Flanagan, C.W., Shen-Gunther, J., Benbrook, D.M.
(1997) Biological assay for activity and
molecular mechanism of retinoids in cervical tumor cells. Gynecologic Oncology, 64(2):312.
17. Flanagan, C., Fishburne, V.H., DiSilvestro, P. Nuñez, E.R., Benbrook, D.M. (1997) Mechanism of
retinoid anc carotenoid
growth inhibition of a cervical tumor cell line. Gynecologic
Oncology, 64(2):357.
18. Benbrook, D.M., Lu, S.
(1997) Retinoid regulation of endogenous
receptors, growth and EGF-R in a cervical carcinoma cell line. Proceedings
of the 88th Annual Meeting of the American Association for Cancer Research,
38:453, abstract #3032.
19. Benbrook, D.M., Nuñez, E.R.
(1997) Differences in radiosensitization
and cell cycle progression of cervical carcinoma cell lines. Proceedings of the 88th Annual
Meeting of the American Association for Cancer Research, 38:44, abstract #296.
20. Benbrook, D.M., Berlin, K.D.,
Birckbichler, P.J. (1997) Correlation of transactivation with growth
inhibition and transglutaminase induction by
heteroarotinoids. Proceedings of the 88th Annual Meeting of the American Association for
Cancer Research, 38:454,
abstract #3037.
21. DiSilvestro, P., Flanagan,
C., Angros, L., Benbrook, D. (1997) Decrease in Ki-67 and epidermal growth factor
receptor expression correlates with retinoic acid induced growth inhibition in
a cervical cancer cell line. Proceedings of the 88th Annual Meeting of the
American Association for Cancer Research, 38:88, abstract #592.
22. Ivey, R. T.,
Brown, D., Berlin, K.D., Benbrook, D.M.
(1998) Retinoid response of two
ovarian carcinoma cell lines. Proceedings of the American Association for
Cancer Research, 39:106-107,
abstract #722.
23. Lu, S., Dhar,
A., Ivey, R.T., Berlin, K.D., Benbrook, D.M. (1998)
Heteroarotinoid structure affects receptor specificity and growth
inhibitory activities. Proceedings of the American Association for
Cancer Research, 39:107,
abstract #723.
24. Zacheis, D.H., Houck,
J.R., Berlin, K.D., Benbrook, D.M.
(1998) Inhibition of the growth
of head and neck squamous cell carcinoma by heteroarotinoids. Fifth
Research Workshop on the Biology, Prevention, and Treatment of Head and Neck
Cancer, Abstract #130.
25. Simms-Kelley,
M. D., Subramanian, S., Spruce, L. W., Madler, M. M.,
Patrick, S. D., Grummer, R., Lemire,
T. D., Benbrook, D. M., Birckbichler, P. J.,
Berlin, K. D., and Nelson, E. C. Growth promoting activity of heteroarotinoids
in vitamin A deficient rats. FASEB J.
12: 450, 1998
26. Dhar, A.,
Berlin, K.D., Madler, M.M., Ivey, R.T., Birckbichler, P.J., Lu, S., Zacheis,
D., and Benbrook, D.M. Flexible Nitrogen Heteroarotinoids: Receptor
specificity and Therapeutic Potential in Epithelial Cancers. American
Association for Cancer Research Annual Meeting, April 10-14, 1999,
Philadelphia, Pennsylvania.
27. Simms-Kelley,
M. D., Subramanian, S., Madler, M. M., Patrick, S.
D., Klucik, J., Browth, C.
E., Liu, S., Lemire, T. D., Benbrook, D. M., Birckbichler, P. J., Berlin, K. D., and Nelson, E. C.
Heteroarotinoids promote growth in vitamin A-deficient rats. FASEB J. 13:647, 1999.
28. Spencer, C., Benbrook,
D.M. “Retinoids induce apoptosis in ovarian organotypic cultures” presented
at the Western Association for Gynecologic Oncologists 1999 Annual
Meeting. Won award for best abstract.
29. Kamelle, S., Sienko, A., Benbrook, D.M.
In vitro representation of endometrium using organotypic culture: A future
model for the study of endometrial carcinogenesis. Society of Gynecologic Oncologists 31st
Annual Meeting, San Diego, CA, February 5-9, 2000, Abstract 85, page 169.
30. Hassan, Benbrook,
D.M. , Lightfoot, S.A., Lerner, M.R., Brackett, D.J., Chowdhury,
P.S., Pastan, I. SS1(DSFV)-PE38, A recombinant anti-mesothelin immunotoxin targets
human gynecologic tumors overexpressing mesothelin.The
36th American Society of Clinical Oncology (ASCO) Annual Meeting,
May 20-23, 2000, New Orleans, LA.
31. Dhar, A., Berlin, K.D., Benbrook, D.M. Structural
Features of Synthetic Retinoids Confer Receptor Selectivity and Refined
Biological Activities. American
Association for Cancer Research Annual Meeting, April 1-5, 2000, San Francisco,
CA.
32. Guruswamy, S., Benbrook, D.M.
Retinoids
Induce Differentiation and Apoptosis in Ovarian Adenocarcinoma
Organotypic Culture. American Association for Cancer Research
Annual Meeting, April 1-5, 2000, San Francisco, CA.
33. Lu, S.,
Benbrook, D.M. (2000) Anti-AP-1 activity of retinoids may not be a contribution
to their growth inhibition activity in some tumor cell lines. Proceedings of the American Association
for Cancer Research, 41:851.
34. Spencer, C. Benbrook,
D.M. “Retinoids induce apoptosis in ovarian organotypic cultures” Presented
at Plenary Session of American Society of Clinical Oncologists (ASCO) 2000
Annual Meeting.
35. Benbrook, D.M. Graphics
illustrating adenoviral p53 gene therapy for ovarian cancer were shown on
"Health Check” presented on News Channel 4, February, 2000.
36. Patrick, S.D.,
Waugh, K., Subramanian, S., Simms-Kelley, M.D., Benbrook, D.M., Berlin,
K.D., Nelson, E.C. Synthetic retinoids
induce differentiation in F9 cells. FASEB, 2000.
37. Kamelle SA, Sienko A, Benbrook D. An in vitro model of normal endometrium using
organotypic culture: The first step in producing a model to study endometrial
carcinogenesis. Society of Gynecologic Oncology (SGO) Annual Meeting 2000
38.
39. Kamelle, S., Sienko, A., Berlin, K.D., Benbrook,
D.M. “Retinoid inhibition of ovarian
cancer xenograft growth” Western
Association of Gynecologic Oncologist (WAGO) Annual Meeting, Monterray, CA, May, 2000.
40. Guruswamy, S.,
Berlin, K.D., Benbrook, D.M. Chemosensitization of two ovarian carcinoma cell lines to
cisplatin by heteroarotinoids.
Proceedings of the American Association for Cancer Research. 42:953-954,
#5127, 2001.
41. Ju, K.-H.,
Benbrook, D.M., Berlin, K.D., Hong, W.K., Lotan, R. Induction of apoptosis in
head and neck squamous cell carcinoma cell (HNSCC) lines by selected
heteroarotinoids. Proceedings of the American Association for Cancer Research.
42:548-549, #2947, 2001.
42. Benbrook, D.M., Sienko, A. A hormonally responsive organtoypic
model of cycling endometrium. Proceedings of the American Association for
Cancer Research. 42:547, #2939, 2001.
43. DuPont, N. Benbrook,
D.M. MUC-1 as an indicator of
cellular differentiation in ovarian cancer,
American College of Obstetricians and Gynecologist (ACOG) District VII
meeting, September 25, 2001, Tulsa, OK.
44. Benbrook, D.M., Kamelle, S.,
Joyce, K., Guruswamy, S., Tillmanns, T., Gould, N., Rutledge, T. Evaluation of
Human Papillomavirus and p53 transcriptional
activation in the mechanism of 9-cis-retinoic acid radiosensitization of
squamous gynecologic cancer cell lines.
Proceedings of the American Association for Cancer Research 43: 433,
#2154, 2002.
45. Guruswamy, S., Benbrook,
D.M. The roles of p53, retinoid
receptors, and DNA damager response genes in the mechanism of retinoid
sensitization of OVCAR-3 to cisplatin.
Proceedings of the American Association for Cancer Research 43: #2150,
2002.
46. DuPont, N. Benbrook
D.M. The Clinical Significance of MUC-1 Expression in Ovarian Cancer".
American College of Obstetricians and Gynecologists District VII meeting,
October 11, 2002, New Orleans, LA.
47. Benbrook, D.M. Both receptor-active and receptor-independent
retinoids regulate of growth, differentiation and apoptosis without toxicity in
an ovarian cancer xenograft model. Proceedings of the American Association for
Cancer Research: 2003.
48. Arendse, C.E.,
Brennan, M., Benbrook, D.M., Hendricks, D.T. Characterisation
of heteroarotinoids as potential agents in the treatment of oesophageal
cancer. IUBMB conference in Toronto,
Ontario, Canada, July 2003
49. Benbrook, D.M. and Lightfoot,
S.L. Reactive Oxygen Species (ROS) are
involved in the mechanism of SHetA2-induced apoptosis but not differentiation
in ovarian cancer organotypic cultures.
Proceedings of the American Association for Cancer Research 45: 2004
50. Lightfoot, S.L.
and Benbrook, D.M. Effects of steroids
and retinoids in an organotypic model of endometrial carcinogenesis. Proceedings of the American Association for
Cancer Research 45: 2004
51. Liu, Z. Covey,
J., Benbrook, D., Chan, K.
“Pharmacokinetic and Metabolism Study of SHetA2 (NSC 683864), a New
Heteroarotinoid Antitumor Agent in the Rat” American Association for Phramaceutical
Sciences (AAPS), Nov., 2004
52. Hannafon, B.N.,
Dearnley, D.D., Benbrook D.M. Gene
Expression of the Angiogenic Factor Thrombospondin 4
can be inhibited by SHetA2 in Ovarian Cancer Cells. MD Anderson 5th
International Conference on Ovarian Cancer, Dec. 1-4, 2004.
53. Dearnley, D.D.,
Hannafon, B.N., Benbrook, D.M. A Novel Chemotherapeutic Agent, SHetA2, Inhibits
Expression of Platelet Derived Endothelial Cell Growth Factor (PD-ECGF) in
Ovarian Cancer and Angiogenesis In Vitro. MD
Anderson 5th International Conference on Ovarian Cancer, Dec. 1-4,
2004.
INVITED LECTURES
1.
“Interaction of CREB and Jun transcription
Factors” September 1991
Department of
Microbiology, Oklahoma State University
2.
“Interaction of CREB and Jun Transcription
Factors” September 1991
Department of
Biochemistry and Molecular Biology, University of Oklahoma
3. “Effects of Retinoids on Organotypically
Grown Tumors” 1993
Department of
Biochemistry and Molecular Biology, Oklahoma State University
4. “The Influence
of Diet and Retinoic Acid on Cancer” 1993
Science Forum, Combined NIH Training Grants
Meeting
Oklahoma Memorial Research Foundation
5.
“Retinoid
Effects on Organotypically Grown Cervical Tumor
Tissue” 1993
Department of
Anatomy, University of Oklahoma
6.
“Radiation and Retinoid Effects on Cervical
Cancer” 1994
Department of
Pathology , University of Oklahoma
7.
“Drug
Discovery and Design” 1994
Premed Club,
University of Oklahoma Undergraduate School, Norman, Oklahoma
8.
"Translational Research: Studying the
Relationship Between Nutrition and Cancer"
November 1995,
Obstetrics and Gynecology Grand Rounds, University of Oklahoma
9.
"The Food You Eat Can Change You” November
1997
The Science
Forum at the Oklahoma Medical Research Foundation
10. “Oncogenes and Tumor Suppressor Genes” May 1997
Obstetrics and
Gynecology Grand Rounds, University of Oklahoma
11. “Oncogenes and Tumor Suppressor Genes” June 1997
Cancer
Conference at INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma
12. “Prevention and
Treatment of Cervical Cancer with Synthetic Retinoids” July 1997
Drug Dynamic
Institute, University of Texas at Austin, Texas
13. "Cancer
Genetics" October 1997
Womens Health
Symposium, Marriot Hotel, Oklahoma City, Oklahoma
14. "Potential
and Molecular Markers for 4HPR in Chemoprevention of Ovarian Cancer"
July 1998, Gynecological Oncology Group Semi-annual
Meeting, Toronto, Ontario
15. "Translational
Research to Develop Retinoids for Gynecological Cancers" September 1998
Department
of Cellular Biology, Lousiana State University,
Shreveport, LA
16. "Translational
Research to Develop Retinoids for Gynecological Cancers" September 1998
Department of
Biochemistry and Molecular Biology, University of Oklahoma HSC
17. "Translational Research to Develop
Retinoids for Gynecological Cancers"
September 1998
Department of
Cellular and Molecular Medicine, University of Ottawa, Ottowa,
Ontario
18. "Translational Research to Develop
Retinoids for Gynecological Cancers" October1998
Oklahoma
Memorial Research Foundation, Oklahoma City, OK
19. "Anti-AP1
activity of Retinoids: Correlation with Growth Inhibition and
Radiosensitization"
Februrary 1999, Steroid
Hormone Receptor Group, Oklahoma City, OK
20. "Organotypic
Culture Models of Gynecological Cancer and Disease" March 1999
Obstetrics and Gynecology Grand Rounds
University of Oklahoma HSC
21. “Adenoviral p53 Gene Therapy for Ovarian Cancer”
February 2000
“Health Check” News Channel 4
22. “Molecular Biological Techniques” February,
2000
Obstetrics and Gynecology Grand Rounds
University of Oklahoma HSC
23. “Molecular Advances in Cancer Therapy” March,
2000
Academy of Medicine, Oklahoma City, OK
24. “Molecular Mechanisms of Retinoids Against
Gynecologic Cancers” June 2000
Federation of the American Association of
Experimental Biology (FASEB)
Special Meeting on Retinoids, Copper Mountain
Colorado
25. “Retinoids, not just for Acne Anymore”
September 2000
Oklahoma Memorial Research Foundation,
Oklahoma City, OK
26. “Molecular Mechanisms of Retinoid Drugs”
October 2000
Shanghai Institute of Biochemistry, Shanghai,
China
27. “Tumor
Suppressor Genes and DNA Tumor Viruses” April, 2001
Annual Spring Meeting of the Texas Section of
the American Association for Clinical Chemistry. Sam Noble Historical Museum, Norman, OK
28. “Retinoids, Apoptosis and Cancer”, June 7,
2001
Policlinico P. Giaccone, Palermo, Italy
29. “Development of Retinoids for Chemoprevention”
June 21, 2001
Dip. Sc. Farmaceutiche,
Ferrara, Italy
30. “Refining Retinoids with Heteroatoms” March
14, 2002
Procter
& Gamble, Cincinnati, OH
31. “Relations of Differentiation, Apoptosis and
MUC1 in Retinoid Growth Inhibition of
Ovarian Cancer” June 24th, 2002
2002 FASEB Summer Research Conferences,
Retinoids, Tucson, AZ
32. “Molecular
Biology of Endometrial Cancer” December 5-6, 2002
Conference on Controversies in the
Management of Gynecologic Malignancies 3, Washington, D.C.
33. “Organotypic
Models of Carcinogenesis”, December 13, 2002
Cancer Group,
Oklahoma Memorial Research Foundation, Oklahoma City, OK
34. “Biomarkers,
Histology & Stem Cells in Endometrial Cycling & Cancer”, February 19,
2003
Gynecologic Oncology Program of the OU
Cancer Center Meeting
Oklahoma Medical Research Foundation
(OMRF)
35. “Understanding
Cancer and Developing New Prevention and Treatment Strategies”,
February 21,
2003
Womens Health Center
Research Meeting
University of Oklahoma Health Sciences
Center
36. "SHetA2
Regulation of Growth, Differentiation and Apoptosis in Cancer Cells and Tumors
without
Evidence of Toxicity", April 1, 2003
National Cancer Institute Rapid Acess to Intervention and Development (RAID) Program,
National Cancer Institute, Bethesda, MD
37. “Carcinogenesis
and Chemoprevention of Gynecologic Cancers”, April 30, 2003
Department of Biochemistry and Molecular
Biology
University of Oklahoma Health Sciences
Center, Oklahoma City, OK
38. “Development of Chemoprevention Drugs that
Regulate Growth, Apoptosis and
Differentiation
in Cancer Cells without Toxicity”. May 6th
Breast Cancer
Program of the OU Cancer Center Meeting
University of
Oklahoma Health Sciences Center
39.
“Translational Research and the Dawn Hope Tissue Bank”, May 12, 2003
Aventis
Site Visit
Section of
Gynecologic Oncology
Departement of Obstetrics
and Gynecology
University of Oklahoma Health
Sciences Center
40.
“Development of Heteroarotinoids for Chemoprevention”, May 19, 2003
Encore Site Visit
Free Radical Biology Section
Oklahoma Medical Research Founcation, Oklahoma City, OK
41. “How to Get an NCI Grant”, September 5, 2003
Grant Writing Workshop
OU Cancer Center,
Oklahoma City, OK
42. “Preclinical Development of SHetA2 for
Cancer”, October 10, 2003
Huntsman Cancer Center, Ovarian
Cancer Research Group
Salt Lake City, Utah
43. “Mechanism of Differentiation and Apoptosis
Induction in Cancer Cells by a Retinoid Receptor-Independent Heteroarotinoid,
SHetA2” FASEB Summer Research Conference
on Retinoids, June 12-17, 2004
44. “Preclinical Development of SHetA2 for
Cancer”, August 23, 2004
Department of Medicine Grand
Rounds, University of Oklahoma HSC
Oklahoma City, OK
45. “Preclinical Development of Flex-Hets”,
December 16, 2004
Section of
Endocrinology Grand Rounds, Department of Medicine, University of Oklahoma HSC,
Oklahoma City, OK